Bristol-Myers Squibb (BMY): Q2 2026 results, my verdict

2026-07-30 · By Lubin Danilo, founder of Lubin Investment

BMY: see the full analysis on Lubin Investment

Bristol-Myers Squibb reported on July 30, 2026 revenue of $13 billion (+6%) and raised its full-year guidance. My quality filter validates 7 out of 10 criteria: profitability is solid, but total growth stays very weak. The real issue is not this quarter: it is the race between new drugs and the patent expiration of old ones.

What just landed: a quarter that beats expectations by a wide margin

Bristol-Myers Squibb released its second-quarter 2026 results on July 30, 2026: revenue of $13 billion, up 6% year over year, and adjusted earnings per share of $2.04, far above analyst expectations. Buoyed by this quarter, the group raised its full-year guidance: revenue is now expected between $49 and $50 billion (versus $48.2 billion in 2025), and adjusted earnings per share between $6.75 and $7.00 (versus $6.15 last year).

The engine of the quarter is what the company calls its Growth Portfolio: newer drugs (Opdivo Qvantig, the subcutaneous formulation, Reblozyl for certain forms of anemia, Camzyos for a specific heart condition, Breyanzi and Opdualag) generated $7.6 billion, up 15% year over year. One notable soft spot: Cobenfy, the antipsychotic launched in 2024 with an entirely new mechanism of action (the first in its category in decades), brought in only $63 million, about 4% below expectations. It remains an early-stage drug on the market: gradual adoption still needs to be confirmed over the coming quarters.

Why my filter validates only 7 out of 10 criteria

On profitability, Bristol-Myers Squibb is solid: net margin of 12.3%, cash profitability (free cash flow margin) of 23.4%, cash return on capital employed (Cash ROCE) of 30.7%, and above all a 190% cash conversion of earnings (the company generates almost twice as much cash as accounting profit, often a sign that net income is weighed down by non-cash charges such as amortization of intangible assets from past acquisitions, not by an actual cash problem). Shares outstanding also shrink 2.19% a year, a sustained buyback pace.

But two criteria fail clearly, and they tell the real story of the pharmaceutical industry: total sales growth rises only 1.3% a year on average over five years, and free cash flow per share only 2.4% a year. This is the patent cliff mechanism: a patent-protected drug can be sold without direct competition for years, generating very high margins, but the day the patent expires, much cheaper generic copies arrive and the drug's revenue collapses within a few quarters. Bristol-Myers Squibb must grow its Growth Portfolio by 15% a year just to offset the decline of its older blockbusters that have reached the end of their protection. For now, the race is roughly being won (total revenue still rising), but narrowly.

The price: not extreme, but the model stays cautious

Bristol-Myers Squibb trades at 11.7 times its annual free cash flow (P/FCF), a level that sits at the 64th percentile of its last five years: neither clearly expensive nor clearly cheap for this specific stock. Yet my reasonable-buy-price model, which projects the five-year cash-per-share trajectory, puts the entry point at $31.97 against a current price of $64.86: a 50.7% premium.

How can a multiple that is not clearly excessive still signal such a large premium? Because my model does not just look at the current multiple: it projects the future cash trajectory, and that trajectory is held back by the very weak free cash flow per share growth (2.4% a year) I just detailed. A P/FCF of 11.7x can look reasonable for a company growing 10% a year; it looks far less reasonable for a company whose cash-per-share growth is stuck at 2.4%. That is the whole point of separating the raw multiple from the trajectory it is financing.

The real debate

The whole Bristol-Myers Squibb thesis comes down to a race: can the Growth Portfolio accelerate enough to offset, then outpace, the structural decline of older drugs? Raising full-year guidance is a good short-term sign. But Cobenfy, the most promising long-term catalyst (a new mechanism of action, a potentially huge psychiatric market), is still disappointing in its early quarters. If Cobenfy accelerates in the coming quarters, the thesis improves markedly; if it keeps disappointing, the patent cliff could regain the upper hand.

How I settle it

I keep Bristol-Myers Squibb on watch rather than as a buy: profitability is real and the quarter reassures in the short term, but my model shows a premium of over 50% once the weak growth trajectory is factored in, and the real catalyst (Cobenfy) has not yet proven itself. This is exactly the kind of nuance I want to be able to judge quickly for any stock, which is why I built my stock analysis site.

Bristol-Myers Squibb validates 7 out of 10 criteria: solid profitability (Cash ROCE 30.7%, 190% cash conversion), but very weak total growth (1.3%/year).
The Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag) climbs 15%/year and, for now, offsets the decline of older drugs past patent protection.
Cobenfy, the new antipsychotic with a novel mechanism, still disappoints ($63M, -4% vs expectations): a key catalyst to watch.
P/FCF of 11.7x (64th percentile, seemingly neither cheap nor expensive), yet a 50.7% premium per my model once weak cash-per-share growth (2.4%/year) is factored in.
Verdict: real profitability, raised full-year guidance, but I stay on the sidelines until Cobenfy confirms its potential.

FAQ

What is the patent cliff?

The moment a drug's patent protection expires: cheaper generics arrive, and the original drug's revenue collapses within a few quarters. Pharmaceutical companies must constantly launch new drugs to offset this decline on older ones.

Why does Bristol-Myers Squibb turn 190% of its earnings into cash?

A rate above 100% means the company generates more cash than accounting profit, often because net income is reduced by non-cash charges such as amortization of intangible assets from past acquisitions. Cash does not lie on this point.

Should you buy Bristol-Myers Squibb stock after these results?

My quality filter is mixed (7/10) and my model shows a 50.7% premium once the weak projected growth is factored in. I would rather wait for Cobenfy to confirm its potential before revisiting my judgment. This is not personalized investment advice, do your own research.

What is Bristol-Myers Squibb's Growth Portfolio?

The group's newer drugs (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag), which must grow fast enough to offset the decline of older blockbusters past patent protection.

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).